- Report
- August 2025
- 186 Pages
Global
From €3158EUR$3,545USD£2,748GBP
€3509EUR$3,939USD£3,053GBP
- Report
- October 2025
- 195 Pages
Global
From €3158EUR$3,545USD£2,748GBP
€3509EUR$3,939USD£3,053GBP
- Report
- October 2025
- 184 Pages
Global
From €3158EUR$3,545USD£2,748GBP
€3509EUR$3,939USD£3,053GBP
- Report
- September 2025
- 250 Pages
Global
From €4000EUR$4,490USD£3,480GBP
- Report
- September 2025
- 250 Pages
Global
From €4000EUR$4,490USD£3,480GBP
- Report
- September 2025
- 250 Pages
Global
From €4000EUR$4,490USD£3,480GBP
- Report
- September 2025
- 250 Pages
Global
From €4000EUR$4,490USD£3,480GBP
- Report
- January 2025
- 175 Pages
Global
From €4000EUR$4,490USD£3,480GBP
- Report
- October 2025
- 105 Pages
Global
From €3500EUR$4,209USD£3,152GBP
- Report
- February 2024
- 118 Pages
Global
From €3500EUR$4,209USD£3,152GBP
- Report
- October 2025
- 50 Pages
Global
From €2361EUR$2,650USD£2,054GBP
- Report
- March 2025
- 109 Pages
China
From €1603EUR$1,800USD£1,395GBP
- Report
- March 2025
- 215 Pages
China
From €3563EUR$4,000USD£3,101GBP

Irbesartan is a medication used to treat high blood pressure and heart failure. It belongs to a class of drugs known as angiotensin receptor blockers (ARBs). ARBs work by blocking the action of a hormone called angiotensin II, which causes blood vessels to narrow and increases blood pressure. Irbesartan is also used to reduce the risk of stroke in people with high blood pressure and left ventricular hypertrophy, a condition in which the heart's left ventricle is enlarged.
Irbesartan is available as a generic drug and is marketed under several brand names, including Avapro, Karvea, and Aprovel. It is available in tablet form and is usually taken once or twice daily.
In the Irbesartan market, some of the companies include Sanofi, Bristol-Myers Squibb, Daiichi Sankyo, and Teva Pharmaceuticals. Show Less Read more